Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
It is generally recommended that women who are planning to become pregnant take a daily supplement of folic acid. Taking this supplement has been associated with reduced risk…
NEW YORK (Reuters Health) – Revised guidelines on the assessment and management of reproductive complications in young female cancer survivors provide the latest evidence-based recommendations for evaluation and…
Alan Greene, MD, Founder, DrGreene.com, discusses the optimal time for umbilical cord clamping, and how early clamping may contribute to iron deficiency anemia in the newborn. Filmed at FutureMed,…
Roger Garcia, DO, Medical Director at BodyLogicMD, in Ohio, discusses how epigenetics can help us understand how we can be in control of changes in our gene expression…
Oriane Chausiaux, PhD, and Shamus Husheer, PhD, explain the hardships faced by 1 in 7 American couples who have difficulties with fertility. These issues range from a lack of…
ZURICH (Reuters) – Swiss pharma group Roche’s drug Perjeta (pertuzumab) significantly extended the lives of women with HER2-positive breast cancer compared to a placebo, according to new data…
The Misfit “Shine” is a new device that empowers people to track their daily activity goals in a simple and elegant way. Sonny Vu and Sridhar Iyengar, co-founders…
Oriane Chausiaux, PhD, and Shamus Husheer, PhD, discuss DuoFertility, a new method to aid couples struggling with infertility. The program monitors over 20,000 physiological measurements to guide couples on the best ways to conceive…
NEW YORK (Reuters Health) – Despite its known cardiotoxic effect, trastuzumab is associated with a relatively low risk of congestive heart failure in women being treated for HER2-positive…
NEW YORK (Reuters Health) – The increased risk of breast cancer in women who received radiotherapy above the diaphragm for treatment of Hodgkin’s lymphoma (HL) persists for at…
